Industry Briefs: September 17, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: September 17, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Almac has launched a new histone reagents catalog and custom synthesis service. Read More

The biopharmaceutical company Bionomics has acquired Eclipse Therapeutics, a stem-cell research company. Read More

Catalent Pharma Solutions and CTC Bio have agreed to provide services to South Korean pharmaceutical companies seeking to commercialize solid oral-dose and controlled-release products in the US and Europe. Read More

Haupt Pharma successfully passed inspections by FDA at four sites in Germany during the first half of 2012. Read More

Recipharm has received regulatory approval from the French health authorities to fill biotechnology products at its site in Monts, France. Read More

Sanofi’s subsidiary Genzyme has received FDA approval for a new molecular entity, Aubagio (teriflunomide), a once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis. Read More

SGS Life Science Services completed an expansion of its Fairfield, New Jersey, facility on Sept. 20, 2012. The expansion enlarges the size of the facility from 15,000 to 30,000 ft2 by adding modernized and new GMP/GLP-compliant laboratories, and increases ICH Zone 1–4 storage capacities.

West has launched B.safe, its syringe-safety system technology system. Read More

People Notes

Emisphere Technologies has appointed Alan L. Rubino as president and CEO, effective immediately. Read More

Patheon has appointed Harry Gill to senior vice-president of quality and continuous improvement. Read More

Unicep, contract packaging company, has announced new ownership with Marcus Anderson, current president, and Clint Marshall, current chief financial officer purchasing the company from its founder, John Snedden. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here